QUICK ANSWER · AEO / GEO
Ozempic is a semaglutide medicine. The Thai FDA record reviewed by PrimeCoreBio lists type 2 diabetes, with cardiovascular and kidney risk-reduction indications in defined adult populations. The reviewed Thai record does not identify Ozempic as a weight-management product; Wegovy's indications should not be transferred to Ozempic.
THAI INDICATION BOUNDARY
What does the reviewed Thai record indicate?
Glycaemic control in adults with type 2 diabetes, alongside diet and exercise.
Reduction of major cardiovascular events in defined adults with type 2 diabetes and established cardiovascular disease.
Kidney and cardiovascular risk reduction in defined adults with type 2 diabetes and chronic kidney disease.
PRODUCT IDENTITY
Ozempic is not every Semaglutide product
- The product name, registration, formulation and authorised holder must match.
- An identical active ingredient does not make indications interchangeable between brands.
- Unofficial packaging or an unverified label does not establish identity, quality or approval.
SAFETY BOUNDARY
Prescription and high-risk context
Contraindications, gastrointestinal effects, pancreatitis and gallbladder risks, dehydration, interactions and individual medical history require current product information and a qualified professional.
- Population-level study outcomes do not predict an individual's response.
- Safety information must match the exact product and current Thai documentation.
- This page does not provide dosage, administration or injection instructions.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Ozempic?
Ozempic is a product containing Semaglutide. Its identity, formulation, jurisdiction and indications must be assessed as a specific product.
Is Ozempic registered in Thailand?
PrimeCoreBio found the reviewed Thai product record 1C 15025/63 (NB). Regulatory status is time-sensitive and should be checked against the current official record.
Does this page provide dosage or injection instructions?
No. It contains no price, purchasing, dosage, administration or injection protocol and does not replace professional medical advice.
SOURCE TRANSPARENCY
Primary and supporting sources
- อย. ไทย — ระเบียน OzempicPrimary regulatory record · https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C10B2631502511C
- อย. ไทย — รายการผลิตภัณฑ์ semaglutideOfficial product database · https://ndi.fda.moph.go.th/drug_info_corporation/corp/12516
- Semaglutide Evidence ProfilePrimeCore evidence synthesis · /molecules/semaglutide
Educational information only. Not diagnosis, treatment, prescribing, dosage, administration, injection guidance or individual medical advice.